Companion Animal Genomics Market

According to Stratistics MRC, the Global Companion Animal Genomics Market is accounted for $2.3 billion in 2026 and is expected to reach $5.1 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Companion Animal Genomics refers to the study and analysis of the complete genetic makeup of companion animals, including dogs, cats, and other domesticated pets, using advanced genomic sequencing and bioinformatics technologies. It involves examining genes, genetic variations, and hereditary traits to understand health predispositions, disease risks, breed characteristics, ancestry, and biological functions. Companion animal genomics supports precision veterinary medicine, breeding optimization, disease prevention, diagnostic development, and personalized healthcare strategies for pets.

Market Dynamics:

Driver:

Hereditary disease screening demand

Growing awareness among breeders, veterinarians, and pet owners of the prevalence and economic impact of inherited genetic disorders in purebred companion animals is driving adoption of genomic screening programs. Kennel clubs and breed associations in major markets are mandating genetic health certifications as conditions of registration and breeding approval. Direct-to-consumer genetic testing platforms have democratized access to information about breed ancestry and disease predisposition. Veterinary practitioners are integrating pre-breeding genomic panels into reproductive health consultations.

Restraint:

Limited veterinary genomics expertise

The scarcity of veterinary professionals with formal training in clinical genomics interpretation constrains the translation of genomic test results into actionable diagnostic and therapeutic decisions. Many practicing veterinarians report uncertainty in communicating genetic risk findings to clients and in designing management protocols based on genetic predisposition data. Continuing education programs in veterinary genomics remain limited in availability and scope. The complexity of polygenic trait interpretation exceeds the analytical capacity of general practice settings without specialist support.

Opportunity:

Personalized veterinary medicine growth

The emergence of personalized veterinary medicine as a clinical paradigm creates substantial expansion opportunities for companion animal genomics across pharmacogenomics, nutritional genomics, and precision treatment planning. Genomic profiling of drug metabolism pathways enables veterinarians to optimize pharmaceutical selection and dosing for individual animals, reducing adverse drug reactions. Nutrigenomic testing informing personalized dietary recommendations represents a high-growth commercial application. Integration of genomic data with electronic health records enables longitudinal precision care management.

Threat:

Data privacy and ethics concerns

Increasing scrutiny of companion animal genomic data ownership, storage, and commercial use is raising ethical and legal concerns among pet owners and advocacy organizations. Questions persist about the permissible secondary use of genetic data collected for primary diagnostic purposes, particularly in research and product development contexts. Regulatory frameworks governing companion animal genomic data handling lag behind commercial practice in many jurisdictions. Publicized incidents of data sharing without explicit consent damage consumer trust and create reputational risks for testing companies.

Covid-19 Impact:

The COVID-19 pandemic initially disrupted companion animal genomics laboratory operations through staffing restrictions and supply chain interruptions, affecting sequencing reagent availability. The pandemic simultaneously accelerated pet adoption globally, substantially enlarging the companion animal population and future addressable market. Post-pandemic, accelerated digital health adoption and increased consumer investment in comprehensive pet health management have sustained demand growth. The crisis also prompted scientific interest in zoonotic transmission genomics, indirectly elevating the profile and public awareness of companion animal genomic science.

The genetic testing kits segment is expected to be the largest during the forecast period

The genetic testing kits segment is expected to account for the largest market share during the forecast period, due to the rapid expansion of direct-to-consumer and veterinary-prescribed testing platforms offering accessible breed, ancestry, and disease screening panels. Consumer demand for at-home sample collection convenience drives kit volume across e-commerce and pet retail channels. Competitive pricing and simplified submission workflows have expanded the addressable population well beyond early adopter demographics. Veterinary practice integration of genetic kit programs provides professional endorsement and repeat purchase channels. Continuous expansion of detectable condition panels and species-specific kit offerings sustains category growth throughout the forecast period.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate, driven by precipitously declining sequencing costs, improving throughput, and expanding clinical applications across companion animal disease diagnosis, pharmacogenomics, and microbiome analysis. Whole-genome and whole-exome sequencing approaches are transitioning from research to clinical veterinary settings as price-per-sample thresholds reach practitioner-accessible levels. Academic and commercial reference database expansion improves variant interpretation accuracy for companion animal genomes. Integration of NGS data with AI-driven clinical decision support tools enhances diagnostic utility and accelerates adoption in specialist veterinary practices and diagnostic laboratory networks.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest companion animal ownership rates, the most advanced veterinary genomics laboratory infrastructure, and the strongest consumer uptake of direct-to-consumer genetic testing services. The United States is home to leading companion animal genomics companies, including Embark Veterinary, Wisdom Panel, and Mars Petcare genetics platforms, which dominate global market revenue. Established kennel club genetic health certification programs generate recurring institutional testing demand. Strong veterinary specialist networks create professional channel distribution for advanced clinical genomic applications. Academic research institutions and commercial genomics companies maintain active companion animal genome database development programs.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding companion animal ownership across China, Japan, South Korea, and Australia, combined with increasing consumer awareness of genetic health screening benefits. Growing middle-class pet owner demographics with high digital engagement represent a receptive consumer base for direct-to-consumer genomic testing platforms. Local veterinary practices in Asia Pacific are adopting genomic disease screening as differentiated premium service offerings. Regional investments in genomic research infrastructure, including government-funded sequencing centers, are expanding local analytical capabilities. Rising purebred pet ownership trends in Asia Pacific create structural demand for hereditary disease certification programs.

Key players in the market

Some of the key players in Companion Animal Genomics Market include Zoetis Inc., Mars, Incorporated, IDEXX Laboratories, Inc., Neogen Corporation, Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Embecta Corp., Genetic Veterinary Sciences, Inc., Basepaws, Inc., Wisdom Panel, Embark Veterinary, Inc., MyDogDNA, EasyDNA and Animal Genetics Inc.

Key Developments:

In May 2026, Embark Veterinary, Inc. launched a comprehensive whole-genome sequencing service for dogs providing over two hundred and thirty hereditary health condition screenings and a complete ancestry composition analysis through a direct-to-consumer platform update.

In April 2026, Illumina, Inc. introduced a companion animal-optimized sequencing workflow for veterinary diagnostic laboratories, reducing whole-genome turnaround time to forty-eight hours and lowering per-sample sequencing costs by thirty percent.

In March 2026, Basepaws, Inc. expanded its feline oral health genomic panel to include microbiome analysis alongside genetic disease screening, providing a combined genomic and microbial health profile for cats through a single at-home sample kit.

Products And Services Covered:
• Genetic Testing Kits
• Instruments and Consumables
• Software and Bioinformatics
• Services

Animal Types Covered:
• Canine
• Feline
• Equine
• Avian and Exotic Pets

Technologies Covered:
• Polymerase Chain Reaction (PCR)
• Microarray
• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Cytogenetics

Applications Covered:
• Breeding Management
• Genetic Disease Identification
• Personalized Medicine
• Forensics and Identification
• Ancestry and Breed Analysis
• Pharmacogenomics

End Users Covered:
• Veterinary Hospitals and Clinics
• Diagnostic Laboratories
• Research Institutes and Universities
• Breeders and Kennel Clubs
• Pet Owners (DTC)

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific   
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances